Aggressive locoregional management of recurrent peritoneal sarcomatosis

Joel M. Baumgartner, Steven A. Ahrendt, James F. Pingpank, Matthew P. Holtzman, Lekshmi Ramalingam, Heather L. Jones, Amer H. Zureikat, Herbert J. Zeh, David L. Bartlett, Haroon A. Choudry

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background and Objectives Peritoneal sarcomatosis responds poorly to systemic chemotherapy and demonstrates high rates of recurrence after resection. We sought to determine perioperative and oncologic outcomes after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) for recurrent sarcomatosis. Methods We reviewed 15 patients undergoing 17 CRS/HIPEC for recurrent sarcomatosis from a prospective database. Results There were four synovial cell sarcomas, five liposarcomas, three leiomyosarcomas, two gastrointestinal stromal tumors (GIST), and three other sarcomas. Adequate cytoreduction (CC-0/1) was achieved in all patients, with a median intra-operative Simplified Peritoneal Carcinomatosis Index of 6 (range: 3-9). Median blood loss and operative time were 1 L (range: 450-5,200) and 402 min (range: 324-680), respectively. Chemoperfusion drug was mitomycin C, cisplatin, or doxorubicin. Significant post-operative complications (Clavien-Dindo III/IV) occurred in four (24%) patients, with no 60-day mortalities and three (18%) 60-day re-admissions. Median intra-abdominal disease-free and overall survival after CRS/HIPEC was 17.2 (95% CI: 2.4-19.7 months) and 22.6 months (95% CI: 6.1-62.6 months), respectively. There was a trend towards delayed recurrence after combined CRS/HIPEC than after prior CRS alone (17.2 months vs. 10.7 months, respectively; P = 0.52). Conclusion Cytoreduction combined with HIPEC may improve loco-regional disease control in patients with recurrent sarcomatosis.

Original languageEnglish (US)
Pages (from-to)329-334
Number of pages6
JournalJournal of Surgical Oncology
Volume107
Issue number4
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Fingerprint

Synovial Sarcoma
Recurrence
Liposarcoma
Gastrointestinal Stromal Tumors
Leiomyosarcoma
Mitomycin
Operative Time
Sarcoma
Doxorubicin
Cisplatin
Disease-Free Survival
Databases
Carcinoma
Drug Therapy
Mortality
Pharmaceutical Preparations

Keywords

  • cytoreduction
  • HIPEC
  • sarcomatosis

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Baumgartner, J. M., Ahrendt, S. A., Pingpank, J. F., Holtzman, M. P., Ramalingam, L., Jones, H. L., ... Choudry, H. A. (2013). Aggressive locoregional management of recurrent peritoneal sarcomatosis. Journal of Surgical Oncology, 107(4), 329-334. https://doi.org/10.1002/jso.23232

Aggressive locoregional management of recurrent peritoneal sarcomatosis. / Baumgartner, Joel M.; Ahrendt, Steven A.; Pingpank, James F.; Holtzman, Matthew P.; Ramalingam, Lekshmi; Jones, Heather L.; Zureikat, Amer H.; Zeh, Herbert J.; Bartlett, David L.; Choudry, Haroon A.

In: Journal of Surgical Oncology, Vol. 107, No. 4, 01.03.2013, p. 329-334.

Research output: Contribution to journalArticle

Baumgartner, JM, Ahrendt, SA, Pingpank, JF, Holtzman, MP, Ramalingam, L, Jones, HL, Zureikat, AH, Zeh, HJ, Bartlett, DL & Choudry, HA 2013, 'Aggressive locoregional management of recurrent peritoneal sarcomatosis', Journal of Surgical Oncology, vol. 107, no. 4, pp. 329-334. https://doi.org/10.1002/jso.23232
Baumgartner JM, Ahrendt SA, Pingpank JF, Holtzman MP, Ramalingam L, Jones HL et al. Aggressive locoregional management of recurrent peritoneal sarcomatosis. Journal of Surgical Oncology. 2013 Mar 1;107(4):329-334. https://doi.org/10.1002/jso.23232
Baumgartner, Joel M. ; Ahrendt, Steven A. ; Pingpank, James F. ; Holtzman, Matthew P. ; Ramalingam, Lekshmi ; Jones, Heather L. ; Zureikat, Amer H. ; Zeh, Herbert J. ; Bartlett, David L. ; Choudry, Haroon A. / Aggressive locoregional management of recurrent peritoneal sarcomatosis. In: Journal of Surgical Oncology. 2013 ; Vol. 107, No. 4. pp. 329-334.
@article{aaaf09a1fca14bae83c22f3d87528c86,
title = "Aggressive locoregional management of recurrent peritoneal sarcomatosis",
abstract = "Background and Objectives Peritoneal sarcomatosis responds poorly to systemic chemotherapy and demonstrates high rates of recurrence after resection. We sought to determine perioperative and oncologic outcomes after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) for recurrent sarcomatosis. Methods We reviewed 15 patients undergoing 17 CRS/HIPEC for recurrent sarcomatosis from a prospective database. Results There were four synovial cell sarcomas, five liposarcomas, three leiomyosarcomas, two gastrointestinal stromal tumors (GIST), and three other sarcomas. Adequate cytoreduction (CC-0/1) was achieved in all patients, with a median intra-operative Simplified Peritoneal Carcinomatosis Index of 6 (range: 3-9). Median blood loss and operative time were 1 L (range: 450-5,200) and 402 min (range: 324-680), respectively. Chemoperfusion drug was mitomycin C, cisplatin, or doxorubicin. Significant post-operative complications (Clavien-Dindo III/IV) occurred in four (24{\%}) patients, with no 60-day mortalities and three (18{\%}) 60-day re-admissions. Median intra-abdominal disease-free and overall survival after CRS/HIPEC was 17.2 (95{\%} CI: 2.4-19.7 months) and 22.6 months (95{\%} CI: 6.1-62.6 months), respectively. There was a trend towards delayed recurrence after combined CRS/HIPEC than after prior CRS alone (17.2 months vs. 10.7 months, respectively; P = 0.52). Conclusion Cytoreduction combined with HIPEC may improve loco-regional disease control in patients with recurrent sarcomatosis.",
keywords = "cytoreduction, HIPEC, sarcomatosis",
author = "Baumgartner, {Joel M.} and Ahrendt, {Steven A.} and Pingpank, {James F.} and Holtzman, {Matthew P.} and Lekshmi Ramalingam and Jones, {Heather L.} and Zureikat, {Amer H.} and Zeh, {Herbert J.} and Bartlett, {David L.} and Choudry, {Haroon A.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1002/jso.23232",
language = "English (US)",
volume = "107",
pages = "329--334",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Aggressive locoregional management of recurrent peritoneal sarcomatosis

AU - Baumgartner, Joel M.

AU - Ahrendt, Steven A.

AU - Pingpank, James F.

AU - Holtzman, Matthew P.

AU - Ramalingam, Lekshmi

AU - Jones, Heather L.

AU - Zureikat, Amer H.

AU - Zeh, Herbert J.

AU - Bartlett, David L.

AU - Choudry, Haroon A.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Background and Objectives Peritoneal sarcomatosis responds poorly to systemic chemotherapy and demonstrates high rates of recurrence after resection. We sought to determine perioperative and oncologic outcomes after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) for recurrent sarcomatosis. Methods We reviewed 15 patients undergoing 17 CRS/HIPEC for recurrent sarcomatosis from a prospective database. Results There were four synovial cell sarcomas, five liposarcomas, three leiomyosarcomas, two gastrointestinal stromal tumors (GIST), and three other sarcomas. Adequate cytoreduction (CC-0/1) was achieved in all patients, with a median intra-operative Simplified Peritoneal Carcinomatosis Index of 6 (range: 3-9). Median blood loss and operative time were 1 L (range: 450-5,200) and 402 min (range: 324-680), respectively. Chemoperfusion drug was mitomycin C, cisplatin, or doxorubicin. Significant post-operative complications (Clavien-Dindo III/IV) occurred in four (24%) patients, with no 60-day mortalities and three (18%) 60-day re-admissions. Median intra-abdominal disease-free and overall survival after CRS/HIPEC was 17.2 (95% CI: 2.4-19.7 months) and 22.6 months (95% CI: 6.1-62.6 months), respectively. There was a trend towards delayed recurrence after combined CRS/HIPEC than after prior CRS alone (17.2 months vs. 10.7 months, respectively; P = 0.52). Conclusion Cytoreduction combined with HIPEC may improve loco-regional disease control in patients with recurrent sarcomatosis.

AB - Background and Objectives Peritoneal sarcomatosis responds poorly to systemic chemotherapy and demonstrates high rates of recurrence after resection. We sought to determine perioperative and oncologic outcomes after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) for recurrent sarcomatosis. Methods We reviewed 15 patients undergoing 17 CRS/HIPEC for recurrent sarcomatosis from a prospective database. Results There were four synovial cell sarcomas, five liposarcomas, three leiomyosarcomas, two gastrointestinal stromal tumors (GIST), and three other sarcomas. Adequate cytoreduction (CC-0/1) was achieved in all patients, with a median intra-operative Simplified Peritoneal Carcinomatosis Index of 6 (range: 3-9). Median blood loss and operative time were 1 L (range: 450-5,200) and 402 min (range: 324-680), respectively. Chemoperfusion drug was mitomycin C, cisplatin, or doxorubicin. Significant post-operative complications (Clavien-Dindo III/IV) occurred in four (24%) patients, with no 60-day mortalities and three (18%) 60-day re-admissions. Median intra-abdominal disease-free and overall survival after CRS/HIPEC was 17.2 (95% CI: 2.4-19.7 months) and 22.6 months (95% CI: 6.1-62.6 months), respectively. There was a trend towards delayed recurrence after combined CRS/HIPEC than after prior CRS alone (17.2 months vs. 10.7 months, respectively; P = 0.52). Conclusion Cytoreduction combined with HIPEC may improve loco-regional disease control in patients with recurrent sarcomatosis.

KW - cytoreduction

KW - HIPEC

KW - sarcomatosis

UR - http://www.scopus.com/inward/record.url?scp=84874260881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874260881&partnerID=8YFLogxK

U2 - 10.1002/jso.23232

DO - 10.1002/jso.23232

M3 - Article

C2 - 23386388

AN - SCOPUS:84874260881

VL - 107

SP - 329

EP - 334

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -